

UNITED STATE DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington,	D.C.	20231	
Tracini igtori,	D. Q.	20201	

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR			ATTORNEY DOCKET NO.
09/551,977	04/14/00	POLO		J	930049.489/1
			7	EXAMINER	
HM12/0212 INTELLECTUAL PROPERTY			LI,B		
CHIRON CORF			[ART UNIT	PAPER NUMBER
4560 HORTON STREET EMERYVILLE CA 94608-2916			1648	5	
				DATE MAILED:	02/12/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trad marks



Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

DATE MAILED:

			2.0. 20202		
SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT		ATTORNEY DOCKET NO.	
1	· · · · · · · · · · · · · · · · · · ·	1	EXAMII	VER	
			ART UNIT	PAPER NUMBER	

Please find below a communication from the EXAMINER in charge of this application.

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

APPLICANT IS GIVEN ONE EXTENDIBLE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Box Gun Li whose telephone number is (703) 30 5-/6.71

Bagun

ALI R. SALIMINER

09/551,977

Application No.: 09/55/9

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINI NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Application is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 18230, May 1, 1990.	licant's FR
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sec Listing" as required by 37 C.F.R. 1.821(c).	quence
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required 37 C.F.R. 1.821(e).	iired by
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, content of the computer readable form does not comply with the requirements of 37 C.F.R. and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."	1.022
5. The computer readable form that has been filed with this application has been found to be cand/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).	lamaged e
6. The paper copy of the "Sequence Listing" is not the same as the computer readable form o "Sequence Listing" as required by 37 C.F.R. 1.821(e).	f the
7. Other:	•
Applicant Must Provide:	
An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".	
An initial or substitute paper copy of the "Sequence Listing", as well as an amendment direction entry into the specification.	ng its
A statement that the content of the paper and computer readable copies are the same and, was applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).	rhere r
For questions regarding compliance to these requirements, please contact:	÷,
For Rules Interpretation, call (703) 308-4216	

For CRF Submission Help, call (703) 308-4212

For Patentin software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE